摘要
目的观察瑞舒伐他汀对代谢综合征(MS)患者载脂蛋白B/载脂蛋白A1(ApoB/ApoAl)的影响。方法将60例MS患者分为两组,瑞舒伐他汀组(30例)给予舒夫坦10mg/d治疗,阿托伐他汀组(30例)给予立普妥20mg/d治疗。随访12周,观察研究前后血脂、血糖、血压、尿白蛋白排泄率(UAER)、体重指数(BMI)、肝功能、肾功能、肌酸激酶、血常规的变化。结果治疗4周后两组分别较治疗前ApoB/ApoA1、ApoB、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL—C)、甘油三酯(TG)显著下降(P均〈0.01),ApoA1、高密度脂蛋白胆固醇(HDL—C)有增高趋势,但差异无统计学意义,余指标两组比较差异无统计学意义。治疗12周后两组分别较治疗前及治疗4周后ApoB/ApoA1、ApoB、TC、LDL-C、TG及收缩压、舒张压、UAER显著下降(P均〈0.01),ApoA1、HDL—C有继续增高趋势,但差异无统计学意义,余指标两组比较差异无统计学意义。结论瑞舒伐他汀可改善MS患者的血脂紊乱,降低ApoB/ApoA1比值。
Objective To observe the effect of rosuvastatin on ApoB/ApoA1 in patients with metablic syndrome(MS). Methods Sixty patients with MS were divided into two groups, 30 patients in rosuvastatin group received schufftan 10 mg/d and 30 cases in atorvastatin group received lipitor 20 mg/d. The blood lipids, plasma glucose, blood pressure, urinary albumin excretion rates(UAER) , body mass index(BMI) , hepatic and renal function, creatine kinase (CK) , blood routine were measured before and after 4-weeks, 12-weeks treatment. Results After 4-weeks treatment, the plasma levels of ApoB/ApoA1, ApoB, TC, LDL-C, TG decreased obviously in both groups (P 〈 0. 01). The plasma levels of ApoA1 and HDL-C tended to increase, but there were no significant differences, other parame- ters were not signifeantly different, the above-mentioned indicators between the two groups at the 4th- week follow-up were not significantly different. After 12-weeks treatment, the plasma levels of ApoB/ ApoA1, ApoB, TC, LDL-C, TG decreased significantly than before treatment and after 4-week follow-up in the two groups, respectively (P 〈 0.01 ), but there were no statistically significant differences in ApoA1, HDL-C, the plasma level of ApoB/ApoA1, ApoB, TC, LDL-C in the rosuvastatin group were lower than those in the atorvastatin group at the 12th-week follow-up (P 〈 0. 05). Conclusions Rosuv- astatin can ameliarate dyslipidemia in MS patients and reduce ApoB/ApoA1 ratio.
出处
《中国实用医刊》
2012年第12期1-3,共3页
Chinese Journal of Practical Medicine